Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ondansetron Transdermal Patch
- Development stage
- Preclinical
- Lead developer
- InteguRx Therapeutics
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
InteguRx Therapeutics is developing a transdermal patch formulation of ondansetron for the treatment of Pregnancy-Induced Nausea and Vomiting (PINV). Ondansetron is a 5-HT3 receptor antagonist that works as an antiemetic. The company utilizes a proprietary skin penetration enhancement system to enable the transdermal delivery of ondansetron, which typically has poor skin permeability. This formulation is designed to deliver therapeutic doses through the skin, providing a non-oral alternative for pregnant women who suffer from severe nausea and vomiting and are unable to tolerate or retain oral medications. By bypassing the gastrointestinal tract, the patch aims to improve treatment adherence and efficacy in patients with severe PINV symptoms.
- Other names
- Ondansetron transdermal system
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)KCNH2 (Voltage-gated potassium channel subfamily H member 2)SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on Ondansetron Transdermal Patch.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ondansetron Transdermal Patch.